All in all, it's been a good year for Lexicon Pharmaceuticals (LXRX).
Although well off its highs, the stock has done well since I last wrote
about its prospects and the company looks to be in stronger shape
today. The real question for Lexicon, though, is whether the company can
produce clinical data that significantly differentiates its candidates
from rival therapies and gives larger pharmaceutical companies a reason
to partner with the company.
Please click here for more:
Lexicon Needs Differentiated Data To Drive Deals And Value
No comments:
Post a Comment